Cargando…

A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis

Background rVIII-SingleChain is a recombinant factor VIII (FVIII) with increased binding affinity to von Willebrand factor compared with other FVIII products. rVIII-SingleChain is indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A. Objectives To collect r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guillet, Benoit, Hassoun, Abel, Wibaut, Bénédicte, Harroche, Annie, Biron-Andréani, Christine, Repesse, Yohan, d'Oiron, Roseline, Tardy, Brigitte, Pan Petesch, Brigitte, Chamouni, Pierre, Gay, Valérie, Fouassier, Marc, Pouplard, Claire, Martin, Cédric, Catovic, Hasan, Delavenne, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113037/ https://www.ncbi.nlm.nih.gov/pubmed/36758611 http://dx.doi.org/10.1055/s-0043-1761449

Ejemplares similares

Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease
por: Rugeri, Lucia, et al.
Publicado: (2022)

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany
por: Olivieri, Martin, et al.
Publicado: (2020)

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A
por: Bonanad, Santiago, et al.
Publicado: (2021)

Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?
por: Allard, Quentin, et al.
Publicado: (2020)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A
por: Calvez, Thierry, et al.
Publicado: (2018)

Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia
por: Tardy, Brigitte, et al.
Publicado: (2020)

P1672: OCCUPATIONAL INTEGRATION OF ADULTS WITH SEVERE HAEMOPHILIA (INTHEMO): A STUDY BASED ON THE FRANCECOAG REGISTRY
por: Nguyen, Ngoc Anh Thu, et al.
Publicado: (2023)

The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes
por: Zotz, Rainer B., et al.
Publicado: (2019)

Surgery in rare bleeding disorders: the prospective MARACHI study
por: Rousseau, Florence, et al.
Publicado: (2023)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

The Glanzmann Thrombasthenia Registry: safety of platelet therapy in patients with Glanzmann thrombasthenia and changes in alloimmunization status
por: Poon, Man-Chiu, et al.
Publicado: (2023)

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study
por: Resseguier, Noémie, et al.
Publicado: (2018)

Mesure magnetique de quadripoles LINAC type VIII
por: Suberlucq, M, et al.
Publicado: (1985)

Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study
por: Vautier, Mathieu, et al.
Publicado: (2016)

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial
por: Tardy-Poncet, Brigitte, et al.
Publicado: (2015)

Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres
por: van Galen, Karin P. M., et al.
Publicado: (2020)

International recommendations on the diagnosis and treatment of acquired hemophilia A
por: Tiede, Andreas, et al.
Publicado: (2020)

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH
por: van Galen, Karin P. M., et al.
Publicado: (2021)

Cogne VIII
por: CERN. Geneva. SPS-LEAR Experiments Committee
Publicado: (1995)

Enrique VIII
por: Bowle, John
Publicado: (1970)

Enrique VIII
por: Erlanger, Philippe, 1903-1987

Hæmatology—VIII
Publicado: (1910)

Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report
por: Nicol, Christophe, et al.
Publicado: (2020)

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
por: Bachelet, Delphine, et al.
Publicado: (2019)

Managing women‐specific bleeding in inherited bleeding disorders: A multidisciplinary approach
por: Mauser‐Bunschoten, Eveline P., et al.
Publicado: (2020)

King Henry VIII /
por: Shakespeare, William, 1564-1616
Publicado: (1968)

Enlargements of the Spleen—VIII
Publicado: (1908)

Enlargements of the Liver.—VIII
Publicado: (1910)

Nature Notes—VIII
Publicado: (1910)

Chapter VIII. Of Tokens
Publicado: (1894)

Situations, VIII : Autour de 68
por: Sartre, Jean-Paul, 1905-1980
Publicado: (1972)

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture
por: Veyradier, Agnès, et al.
Publicado: (2016)

International consensus recommendations on the management of people with haemophilia B
por: Hart, Daniel P., et al.
Publicado: (2022)

VIII. symfonie G dur = VIII. symphonie G Dur : Op. 88
por: Dvoérák, Antonín, 1841-1904
Publicado: (1956)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Long-Term Antithrombotic Treatments Prescribed for Cardiovascular Diseases in Patients with Hemophilia: Results from the French Registry
por: Guillet, Benoît, et al.
Publicado: (2021)

Management of a High-Risk Surgery with Emicizumab and Factor VIII in a Child with a Severe Hemophilia A and Inhibitor
por: Lefèvre, Charles R., et al.
Publicado: (2021)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e81qpe92idtjp7v7in4d8nkno9